ADMA250516C14000
- 10.12
- 0.000.00%
ADMA Biologics Newsroom
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $35
Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $32
Express News | Raymond James Maintains Strong Buy on ADMA Biologics, Raises Price Target to $32
ADMA Biologics Analyst Ratings
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings
Express News | ADMA Biologics Inc : Mizuho Raises Target Price to $35 From $32
ADMA Biologics Q1 Earnings, Revenue Rise; Shares Fall After Hours
ADMA Biologics | 10-Q: Quarterly report
ADMA Biologics Announces $500M Share Repurchase Program
ADMA Biologics Reports 40% Increase in 1Q 2025 Revenue, Announces $500 Million Share Repurchase Program and Upgraded Financial Guidance
ADMA Biologics | 8-K: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
Express News | ADMA Biologics Inc - FY 2025 & 2026 Revenue Guidance Increased to Over $500 Mln & $625 Mln, Respectively
Express News | ADMA Biologics Inc - Authorizes $500 Million Share Repurchase Program
Express News | ADMA Biologics Q1 Adjusted Ebitda USD 47.9 Million
Press Release: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
ADMA Biologics 1Q EPS 11c >ADMA
Adma Biologics Options Imply 10.9% Move in Share Price Post-earnings
Here Are the Major Earnings After the Close Today
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
Unusual Options Activity: DG, ROIV and Others Attract Market Bets, DG V/OI Ratio Reaches 100.0